GLP-1 Drug Safety
Latest in GLP-1 Drug Safety· Nov 10
The FDA has mandated that GLP-1 makers add warnings about a rare eye condition linked to blindness, creating immediate liability exposure for Novo Nordisk and Eli Lilly while signaling emerging safety signals from clinical use. The vision-loss warnings on Wegovy and Zepbound will trigger litigation and erode consumer confidence in a drug class that has sustained premium pricing and sales growth in the weight-loss market. If safety concerns deter prescribing or patient uptake, demand destruction follows as the competitive weight-loss segment depends on safety perception to drive adoption.
Safety concerns, adverse effects, and regulatory scrutiny surrounding GLP-1 receptor agonist medications including potential vision loss and other health risks.
4 events tracked
- Single source4 days ago
FDA requires GLP-1 makers to warn of blindness-linked eye condition
Regulators order GLP-1 drug makers to add warnings for rare eye condition linked to vision loss.
BBC News
- Single source5 days ago
FDA flags possible vision problems tied to Wegovy, Zepbound weight-loss drugs
FDA warns GLP-1 drugs including Wegovy and Zepbound carry vision loss risk.
CNBC
- Single source8 days ago
Study links replacement plastic chemicals to reduced fetal weight
Research finds Dinch, marketed as a safer plasticizer in food packaging, associated with smaller babies and developmental harm.
The Guardian
- Single sourceabout 2 months ago
Ozempic patients advised to undergo regular eye screenings for potential sight complications
Ozempic users should get routine eye exams to assess vision loss risk, per MarketWatch health guidance.
MarketWatch